There is no difference in metastatic incidence between ER− breast cancer patients with or without elevated miR-19a expression (Fig. 1b), and both miR-133b and miR-576-5p are not significantly associated with metastasis in either ER+ or ER− patients (Supplementary Fig. 2a). This evidence concerns the gene ESR1 and breast carcinoma.